Back to Home

about

Proven safety based on 12+ years of clinical research

About Us

  • Based in the United States, NeuroEnergy Ventures (NEV) was founded in 2016 as a scientific philanthropy. From the beginning, NEV’s focus has been on research and development of ketone-based medical foods and related compounds for people with reduced neuronal metabolism.
  • Neuridan™ is built on decades of research by Sami Hashim, M.D., a renowned authority in brain nutrition, and now a professor emeritus of the Icahn School of Medicine affiliated with Mount Sinai Morningside and Mount Sinai West Hospitals in New York.
  • NEV is now working to commercialize its innovative medical food for the dietary management of numerous neurodegenerative diseases, starting with Alzheimer’s Disease, as well as other conditions requiring delivery of additional energy to the human brain.
  • Additional applications for NEV’s medical food product are in development.
  • Initial availability of Neuridan™ is expected in the fourth quarter of 2024 with a limited rollout in selected U.S. locations. Neuridan™ is expected to 
be prescribed by primary care physicians or neurologists in conjunction with recommendations to address cognition and memory loss as part of a treatment plan that may also include dietary and exercise regimens.

NEV Intellectual Property Portfolio

NEV holds a large portfolio of patents covering its medical food and related biomedical innovations. These include 38 granted patents and 23 pending patent applications for glyceride esters used in the treatment of diseases associated with reduced neuronal metabolism of glucose and other medical indications.